Research progress in the relationship between microbial communities and breast cancer in human tissues

doi:10.3760/cma.j.cn371439-20240727-00132

Abstract

Abstract:

Breast cancer， as a malignant tumor with a high incidence rate in women， seriously endangers the life health and safety of women. Its pathogenesis and treatment strategies are still the hot and difficult points in current research. More and more studies have shown that the occurrence and development of breast cancer is closely related to the microbial community in intestinal tissue and breast tissue， and the microbial community in human tissue may promote or inhibit the occurrence of breast cancer through various ways and mechanisms. Defining the relationship between microbial communities and breast cancer will provide new directions for the prevention and comprehensive treatment of breast cancer.

Key words: Breast neoplasms, Microbial consortia, Gastrointestinal microbiome, Lactobacillus rhamnosus

Zhou Mingrui, Qi Mengqi, Zhang Yanyan, Shi Yinuan, Yue Chuan, Zhang Yan, Liu Xianqiang, Zhang Yan. Research progress in the relationship between microbial communities and breast cancer in human tissues[J]. Journal of International Oncology, 2024, 51(12): 779-784.

References 54

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[3]	Sukumar J, Kassem M, Agnese D, et al. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series[J]. Breast Cancer Res Treat, 2021, 186(2): 569-575. DOI: 10.1007/s10549-021-06095-w.
[4]	Schluter J, Peled JU, Taylor BP, et al. The gut microbiota is associated with immune cell dynamics in humans[J]. Nature, 2020, 588(7837): 303-307. DOI: 10.1038/s41586-020-2971-8.
[5]	Wu Y, Zhang Y, Zhang W, et al. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier[J]. J Cancer Res Clin Oncol, 2023, 149(13): 12513-12534. DOI: 10.1007/s00432-023-05014-4. pmid: 37382675
[6]	Bernardo G, Le Noci V, Di Modica M, et al. The emerging role of the microbiota in breast cancer progression[J]. Cells, 2023, 12(15): 1945. DOI: 10.3390/cells12151945.
[7]	Perler BK, Friedman ES, Wu GD. The role of the gut microbiota in the relationship between diet and human health[J]. Annu Rev Physiol, 2023, 85: 449-468. DOI: 10.1146/annurev-physiol-031522-092054.
[8]	Ahn J, Hayes RB. Environmental influences on the human microbiome and implications for noncommunicable disease[J]. Annu Rev Public Health, 2021, 42: 277-292. DOI: 10.1146/annurev-publhealth-012420-105020.
[9]	Wu AH, Tseng C, Vigen C, et al. Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study[J]. Breast Cancer Res Treat, 2020, 182(2): 451-463. DOI: 10.1007/s10549-020-05702-6.
[10]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494): 973-980. DOI: 10.1126/science.aay9189. pmid: 32467386
[11]	Wang N, Sun T, Xu J. Tumor-related microbiome in the breast microenvironment and breast cancer[J]. J Cancer, 2021, 12(16): 4841-4848. DOI: 10.7150/jca.58986. pmid: 34234854
[12]	Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review[J]. Antonie Van Leeuwenhoek, 2020, 113(12): 2019-2040. DOI: 10.1007/s10482-020-01474-7.
[13]	Song X, Wei C, Li X. The relationship between microbial community and breast cancer[J]. Front Cell Infect Microbiol, 2022, 12: 849022. DOI: 10.3389/fcimb.2022.849022.
[14]	Zhang Z, Tang H, Chen P, et al. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome[J]. Signal Transduct Target Ther, 2019, 4: 41. DOI: 10.1038/s41392-019-0074-5.
[15]	Komorowski AS, Pezo RC. Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment[J]. Breast Cancer Res Treat, 2020, 179(2): 287-300. DOI: 10.1007/s10549-019-05472-w.
[16]	Wu Z, Pfeiffer RM, Byrd DA, et al. Associations of circulating estrogens and estrogen metabolites with fecal and oral microbiome in postmenopausal women in the Ghana breast health study[J]. Microbiol Spectr, 2023, 11(4): e0157223. DOI: 10.1128/spectrum.01572-23.
[17]	Simin J, Tamimi RM, Engstrand L, et al. Antibiotic use and the risk of breast cancer: a systematic review and dose-response Meta-analysis[J]. Pharmacol Res, 2020, 160: 105072. DOI: 10.1016/j.phrs.2020.105072.
[18]	Xiao L, Chi D, Sheng G, et al. Inhibitory effects of UDP-glucuronosyltransferase(UGT) typical ligands against E. coli beta-glucuronidase(GUS)[J]. RSC Adv, 2020, 10(39): 22966-22971. DOI: 10.1039/d0ra02311f.
[19]	Munteanu C, Schwartz B. Interactions between dietary antioxidants, dietary fiber and the gut microbiome: their putative role in inflammation and cancer[J]. Int J Mol Sci, 2024, 25(15): 8250. DOI: 10.3390/ijms25158250.
[20]	Nakatsu G, Andreeva N, MacDonald MH, et al. Interactions between diet and gut microbiota in cancer[J]. Nat Microbiol, 2024, 9(7): 1644-1654. DOI: 10.1038/s41564-024-01736-4.
[21]	Arnone AA, Wilson AS, Soto-Pantoja DR, et al. Diet modulates the gut microbiome, metabolism, and mammary gland inflammation to influence breast cancer risk[J]. Cancer Prev Res (Phila), 2024, 17(9): 415-428. DOI: 10.1158/1940-6207.CAPR-24-0055.
[22]	Dutta RK, Abu YF, Tao J, et al. Altered gut microbiome drives heightened pain sensitivity in a murine model of metastatic triple-negative breast cancer[J]. Am J Cancer Res, 2024, 14(1): 274-299. DOI: 10.62347/LUJF9626. pmid: 38323292
[23]	Gur C, Maalouf N, Shhadeh A, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1[J]. Oncoimmunology, 2019, 8(6): e1581531. DOI: 10.1080/2162402X.2019.1581531.
[24]	Dohrn G. Gut microbes linked to fatty diet drive tumour growth[J]. Nature, 2024, In press. DOI: 10.1038/d41586-024-01443-4.
[25]	Sampsell K, Hao D, Reimer RA. The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship[J]. Int J Mol Sci, 2020, 21(23): 9239. DOI: 10.3390/ijms21239239.
[26]	Raza MH, Gul K, Arshad A, et al. Microbiota in cancer development and treatment[J]. J Cancer Res Clin Oncol, 2019, 145(1): 49-63. DOI: 10.1007/s00432-018-2816-0. pmid: 30542789
[27]	Eslami-S Z, Majidzadeh-A K, Halvaei S, et al. Microbiome and breast cancer: new role for an ancient population[J]. Front Oncol, 2020, 10: 120. DOI: 10.3389/fonc.2020.00120. pmid: 32117767
[28]	Jaye K, Li CG, Chang D, et al. The role of key gut microbial metabolites in the development and treatment of cancer[J]. Gut Microbes, 2022, 14(1): 2038865. DOI: 10.1080/19490976.2022.2038865.
[29]	Su X, Gao Y, Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity[J]. Front Immunol, 2023, 14: 1127743. DOI: 10.3389/fimmu.2023.1127743.
[30]	Urbaniak C, Gloor GB, Brackstone M, et al. The microbiota of breast tissue and its association with breast cancer[J]. Appl Environ Microbiol, 2016, 82(16): 5039-5048. DOI: 10.1128/AEM.01235-16.
[31]	Meng Z, Ye Z, Zhu P, et al. New developments and opportunities of microbiota in treating breast cancers[J]. Front Microbiol, 2022, 13: 818793. DOI: 10.3389/fmicb.2022.818793.
[32]	Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy[J]. Nat Rev Clin Oncol, 2023, 20(7): 429-452. DOI: 10.1038/s41571-023-00766-x. pmid: 37169888
[33]	Zhang YX, Liang ZZ, Li YQ, et al. Association between weight change and breast cancer prognosis[J]. Breast Cancer Res Treat, 2022, 193(3): 677-684. DOI: 10.1007/s10549-022-06592-6.
[34]	Summer M, Sajjad A, Ali S, et al. Exploring the underlying correlation between microbiota, immune system, hormones, and inflammation with breast cancer and the role of probiotics, prebiotics and postbiotics[J]. Arch Microbiol, 2024, 206(4): 145. DOI: 10.1007/s00203-024-03868-x.
[35]	Ma C, Wasti S, Huang S, et al. The gut microbiome stability is altered by probiotic ingestion and improved by the continuous supplementation of galactooligosaccharide[J]. Gut Microbes, 2020, 12(1): 1785252. DOI: 10.1080/19490976.2020.1785252.
[36]	Mendoza L. Potential effect of probiotics in the treatment of breast cancer[J]. Oncol Rev, 2019, 13(2): 422. DOI: 10.4081/oncol.2019.422.
[37]	Vincenzi A, Goettert MI, Volken de Souza CF. An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-α) signa-ling and gene expression[J]. Cytokine Growth Factor Rev, 2021, 57: 27-38. DOI: 10.1016/j.cytogfr.2020.10.004.
[38]	Perales-Puchalt A, Perez-Sanz J, Payne KK, et al. Frontline science: microbiota reconstitution restores intestinal integrity after cisplatin therapy[J]. J Leukoc Biol, 2018, 103(5): 799-805. DOI: 10.1002/JLB.5HI1117-446RR.
[39]	Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy[J]. J Immunother Cancer, 2019, 7(1): 108. DOI: 10.1186/s40425-019-0574-4.
[40]	Vafa S, Zarrati M, Malakootinejad M, et al. Calorie restriction and synbiotics effect on quality of life and edema reduction in breast cancer-related lymphedema, a clinical trial[J]. Breast, 2020, 54: 37-45. DOI: 10.1016/j.breast.2020.08.008. pmid: 32898787
[41]	Thet D, Areepium N, Siritientong T. Effects of probiotics on chemotherapy-induced diarrhea[J]. Nutr Cancer, 2023, 75(10): 1811-1821. DOI: 10.1080/01635581.2023.2267779.
[42]	Shiao SL, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy[J]. Cancer Cell, 2021, 39(9): 1202-1213, e6. DOI: 10.1016/j.ccell.2021.07.002. pmid: 34329585
[43]	Juan Z, Chen J, Ding B, et al. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial[J]. Eur J Cancer, 2022, 161: 10-22. DOI: 10.1016/j.ejca.2021.11.006. pmid: 34896904
[44]	Mirzadeh MA, Eslami M, Ghanbari A, et al. Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects[J]. Med Oncol, 2024, 41(5): 111. DOI: 10.1007/s12032-024-02346-0.
[45]	Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J]. Cell, 2022, 185(16): 2879-2898, e24. DOI: 10.1016/j.cell.2022.07.003. pmid: 35931020
[46]	Álvarez-Mercado AI, Del Valle Cano A, Fernández MF, et al. Gut microbiota and breast cancer: the dual role of microbes[J]. Cancers (Basel), 2023, 15(2): 443. DOI: 10.3390/cancers15020443.
[47]	Yi DY, Kim SY. Human breast milk composition and function in human health: from nutritional components to microbiome and microRNAs[J]. Nutrients, 2021, 13(9): 3094. DOI: 10.3390/nu13093094.
[48]	Parida S, Wu S, Siddharth S, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes[J]. Cancer Discov, 2021, 11(5): 1138-1157. DOI: 10.1158/2159-8290.CD-20-0537. pmid: 33408241
[49]	Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression[J]. Nat Commun, 2020, 11(1): 3259. DOI: 10.1038/s41467-020-16967-2.
[50]	Devoy C, Flores Bueso Y, Tangney M. Understanding and harnessing triple-negative breast cancer-related microbiota in oncology[J]. Front Oncol, 2022, 12: 1020121. DOI: 10.3389/fonc.2022.1020121.
[51]	Bose D, Banerjee S, Singh RK, et al. Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells[J]. Cell Death Dis, 2020, 11(11): 996. DOI: 10.1038/s41419-020-03203-4.
[52]	Banerjee S, Wei Z, Tian T, et al. Prognostic correlations with the microbiome of breast cancer subtypes[J]. Cell Death Dis, 2021, 12(9): 831. DOI: 10.1038/s41419-021-04092-x.
[53]	Zhang Y, Zhou M, Sun J. A novel prognostic signature and potential therapeutic drugs based on tumor immune microenvironment characterization in breast cancer[J]. Heliyon, 2023, 9(10): e20798. DOI: 10.1016/j.heliyon.2023.e20798.
[54]	Naderi N, Mosahebi A, Williams NR. Microorganisms and breast cancer: an in-depth analysis of clinical studies[J]. Pathogens, 2023, 13(1): 6. DOI: 10.3390/pathogens13010006.